

<b>Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/932,802	HALL ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Prema M. Mertz	1646	

All participants (applicant, applicant's representative, PTO personnel):

(1) Prema M. Mertz (Primary Examiner). (3)\_\_\_\_\_.

(2) Doyle A. Siever (Attorney). (4)\_\_\_\_\_.

Date of Interview: 03 August 2005.

Type: a) ☒ Telephonic b) ☐ Video Conference  
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☐ No.

If Yes, brief description: \_\_\_\_\_.

Claim(s) discussed: 25-102.

Identification of prior art discussed: none.

Agreement with respect to the claims f) ☐ was reached. g) ☐ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Prema Mertz  
Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Mr. Siever indicated that for claims 25-102 the earliest priority document was US Provisional application No. 60/051,916 which disclosed a 66 amino acid C-terminal fragment of the 111 amino acid protein of SEQ ID NO:235 (Table I, page 54 of 60/051,916). Mr. Siever requested the Examiner to examine the application after considering a soon-to-be submitted preliminary amendment in which the claims would be amended to encompass an antibody to a protein consisting of the 66 C-terminal amino acids of SEQ ID NO:235.